Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* An informed consent document signed and dated by the subject~* Age 18 to 55 years, inclusive~* In good health with no history of major medical conditions~* A total body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m\^2 and ≤ 30kg/m\^2~Exclusion Criteria:~* Pregnant or nursing females~* Acute or chronic medical illness~* Abnormal lung function~* Positive for human immunodeficiency virus (HIV), active hepatitis A, B or C test~* Nose or nasopharynx abnormalities~* Receipt of any investigational drug within 3 months prior to the planned date of viral challenge/first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- EDP-938 Arm A (Type: EXPERIMENTAL): Subjects will take EDP-938 Dose 1 oral suspension for 5 days
- EDP-938 Arm B (Type: EXPERIMENTAL): Subjects will take EDP-938 Dose 2 oral suspension for 5 days
- Placebo Arm C (Type: PLACEBO_COMPARATOR): Subjects will take matching placebo oral suspension for 5 days
- EDP-938 Arm D (Type: EXPERIMENTAL): Subjects will take EDP-938 Dose 3 oral suspension for 5 days
- EDP-938 Arm E (Type: EXPERIMENTAL): Subjects will take EDP-938 Dose 4 oral suspension for 5 days
- Placebo Arm F (Type: PLACEBO_COMPARATOR): Subjects will take matching placebo oral suspension for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).